A Comparison of Two Standard Therapies in the Management of Dementia With Agitation

• Status: Completed
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether an antipsychotic medication alone or an antipsychotic medication in combination with divalproex is the most effective and safest way to treat agitation in elderly patients with dementia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Emory University
• Collaborator: Abbott
• Treatments: Olanzapine; Quetiapine Fumarate; Risperidone; Valproic Acid

Criteria

Inclusion Criteria:

• inpatients admitted to Wesley Woods Inpatient service for Dementia with psychosis and agitation; taking risperidone (up to 1.5 mg/day), quetiapine (up to 175 mg/day), or olanzapine (up to 7.5 mg/day)

Exclusion Criteria:

• prior sensitivity to risperidone, quetiapine, olanzapine or divalproex